Spot Ether ETF Launch Shifted to July 2nd Amid SEC Feedback

Bloomberg analyst Eric Balchunas has announced that the highly anticipated Spot Ethereum ETF may be approved by the SEC by July 2nd as posted on his official X account. After recent discussions with the SEC, it was revealed that the review process for S-1 filings is progressing well, with only minor adjustments needed, expected to be resolved within the next week.

Read Also: Analyst Prediction: Toncoin (TON) to Surge 40% Based on Bullish Chart Patterns

SEC Feedback

The SEC has been providing feedback on the filings, signalling an effort to expedite the review process. There’s a possibility that they will work to declare them effective by next week and clear them off their plate before the holiday weekend.

SEC Chair Comments

During a Senate Appropriations Committee Hearing, SEC Chair Gary Gensler commented on the potential timeline for Ether ETF approvals, predicting that approvals could happen over the summer. This sentiment was echoed by Senator Bill Hagerty, expressing optimism that the process would be concluded by the end of the summer.

Conclusion

In summary, the launch of Ether ETFs is expected to open new avenues for institutional investors, offering a compliant way to invest in crypto assets. Similar to the earlier approval of Bitcoin-based ETFs, this move is anticipated to significantly influence market trends. The arrival of Ether ETFs could mark a new chapter in cryptocurrency investments, offering increased liquidity and new opportunities for investors.

Read Also: Notcoin (NOT) Rockets Up by 10% as TON Nears Ethereum’s Active Wallet Numbers


Follow us on Twitter, FacebookTelegram, and Google News

  • 206 Posts
  • 0 Comments
Kayode Michael is a seasoned cryptocurrency analyst, successful trader, and skilled writer with a strong command of cryptocurrency analysis and price action. He leverages his technical analysis skills to provide valuable insights into emerging market trends and potential opportunities for investors to make informed decisions.
Loading...